Case-Control Viramune (Nevirapine) Toxicogenomics Study
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Attempt to identify genetic polymorphisms in interrogated pathways which may be associated
with symptomatic hepatotoxicity or severe cutaneous toxicity observed in case patients within
the first 8 weeks of nevirapine therapy.